Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest Expenses (2016 - 2017)

Corcept Therapeutics' Interest Expenses history spans 2 years, with the latest figure at $98000.0 for Q2 2017.

  • For Q2 2017, Interest Expenses fell 81.54% year-over-year to $98000.0; the TTM value through Mar 2018 reached $98000.0, down 81.54%, while the annual FY2011 figure was $25000.0, 0.0% changed from the prior year.
  • Interest Expenses for Q2 2017 was $98000.0 at Corcept Therapeutics, down from $531000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $531000.0 in Q2 2016 and bottomed at $98000.0 in Q2 2017.